Bortezomib in autoimmune hemolytic anemia and beyond

Bortezomib is a first-in-class, potent, selective and reversible proteasome inhibitor approved for the treatment of multiple myeloma (MM) and relapsed/refractory mantle cell lymphoma. In these diseases, bortezomib targets plasma cells and lymphocytes reducing tumor burden. Recently, preclinical evid...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Raffaella Pasquale, Juri Alessandro Giannotta, Wilma Barcellini, Bruno Fattizzo
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/05583e8797654fc48edb971217a231d8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:05583e8797654fc48edb971217a231d8
record_format	dspace
spelling	oai:doaj.org-article:05583e8797654fc48edb971217a231d82021-11-15T04:03:34ZBortezomib in autoimmune hemolytic anemia and beyond2040-621510.1177/20406207211046428https://doaj.org/article/05583e8797654fc48edb971217a231d82021-11-01T00:00:00Zhttps://doi.org/10.1177/20406207211046428https://doaj.org/toc/2040-6215Bortezomib is a first-in-class, potent, selective and reversible proteasome inhibitor approved for the treatment of multiple myeloma (MM) and relapsed/refractory mantle cell lymphoma. In these diseases, bortezomib targets plasma cells and lymphocytes reducing tumor burden. Recently, preclinical evidence highlighted its efficacy in reducing long-lived plasma cells responsible of autoantibodies production in several models of autoimmune conditions. These findings paved the way to a number of experiences of bortezomib use in patients with various autoimmune conditions, including autoimmune hemolytic anemia (AIHA). The latter is a nice model of autoimmunity in hematology and is caused by the production of autoantibodies against erythrocytes resulting in various degrees of hemolytic anemia. AIHA is classified in warm and cold forms according to the thermal characteristics of the autoantibody, and first-line treatment mainly relies on steroids for warm cases and the anti-CD20 rituximab for cold ones. Relapsed/refractory cases are still an unmet need, and bortezomib has been proposed in this setting with intriguing efficacy. In this review, we collected available literature on bortezomib use in AIHA and in other immune-mediated hematologic and non-hematologic diseases. Overall, most experiences highlight bortezomib efficacy even in multi-relapsed/refractory patients and suggest to consider its use in AIHA after rituximab failure.Raffaella PasqualeJuri Alessandro GiannottaWilma BarcelliniBruno FattizzoSAGE PublishingarticleDiseases of the blood and blood-forming organsRC633-647.5ENTherapeutic Advances in Hematology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Raffaella Pasquale Juri Alessandro Giannotta Wilma Barcellini Bruno Fattizzo Bortezomib in autoimmune hemolytic anemia and beyond
description	Bortezomib is a first-in-class, potent, selective and reversible proteasome inhibitor approved for the treatment of multiple myeloma (MM) and relapsed/refractory mantle cell lymphoma. In these diseases, bortezomib targets plasma cells and lymphocytes reducing tumor burden. Recently, preclinical evidence highlighted its efficacy in reducing long-lived plasma cells responsible of autoantibodies production in several models of autoimmune conditions. These findings paved the way to a number of experiences of bortezomib use in patients with various autoimmune conditions, including autoimmune hemolytic anemia (AIHA). The latter is a nice model of autoimmunity in hematology and is caused by the production of autoantibodies against erythrocytes resulting in various degrees of hemolytic anemia. AIHA is classified in warm and cold forms according to the thermal characteristics of the autoantibody, and first-line treatment mainly relies on steroids for warm cases and the anti-CD20 rituximab for cold ones. Relapsed/refractory cases are still an unmet need, and bortezomib has been proposed in this setting with intriguing efficacy. In this review, we collected available literature on bortezomib use in AIHA and in other immune-mediated hematologic and non-hematologic diseases. Overall, most experiences highlight bortezomib efficacy even in multi-relapsed/refractory patients and suggest to consider its use in AIHA after rituximab failure.
format	article
author	Raffaella Pasquale Juri Alessandro Giannotta Wilma Barcellini Bruno Fattizzo
author_facet	Raffaella Pasquale Juri Alessandro Giannotta Wilma Barcellini Bruno Fattizzo
author_sort	Raffaella Pasquale
title	Bortezomib in autoimmune hemolytic anemia and beyond
title_short	Bortezomib in autoimmune hemolytic anemia and beyond
title_full	Bortezomib in autoimmune hemolytic anemia and beyond
title_fullStr	Bortezomib in autoimmune hemolytic anemia and beyond
title_full_unstemmed	Bortezomib in autoimmune hemolytic anemia and beyond
title_sort	bortezomib in autoimmune hemolytic anemia and beyond
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/05583e8797654fc48edb971217a231d8
work_keys_str_mv	AT raffaellapasquale bortezomibinautoimmunehemolyticanemiaandbeyond AT jurialessandrogiannotta bortezomibinautoimmunehemolyticanemiaandbeyond AT wilmabarcellini bortezomibinautoimmunehemolyticanemiaandbeyond AT brunofattizzo bortezomibinautoimmunehemolyticanemiaandbeyond
_version_	1718428846226669568

Bortezomib in autoimmune hemolytic anemia and beyond

Ejemplares similares